Financial woes reduce AstraZeneca's industry profile

Suffering from a dramatic tailspin in drug sales, AstraZeneca ($AZN) will be shrinking its profile at pharma industry events. The pharma giant has banned all "non-essential" travel overseas and reduced its events team in London from 6 to only two, according to Conference & Incentive Travel. An AstraZeneca spokesperson said that the company is planning far fewer events, so doesn't need the same size staff. The pharma company has been laying off thousands of workers as it tries to restructure its pipeline effort and start winning new drug approvals. Story


Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.